Dulaglutide · source year
6 selected, source-linked Dulaglutide records carrying a 2022 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
3 represented types.
6 distinct public records.
Cited chronology
Regulatory
DailyMed lists Structured Product Labeling version 47 for the reviewed Dulaglutide label family with a published date of 2022-12-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
DailyMed lists Structured Product Labeling version 46 for the reviewed Dulaglutide label family with a published date of 2022-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PubMed lists PMID 34866291 in Diabetes, obesity & metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-12-19 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory
DailyMed lists Structured Product Labeling version 45 for the reviewed Dulaglutide label family with a published date of 2022-06-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Safety
FDA's dated enforcement report D-0884-2022 lists Class II and source status Completed for Cardinal Health Inc. PeptideScanner connects the report to reviewed application BLA125469 through exact openFDA application-number annotations.
Regulatory
DailyMed lists Structured Product Labeling version 42 for the reviewed Dulaglutide label family with a published date of 2022-02-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.